@article {Gao1285, author = {Min Gao and Naiyi Zhang and Nan Song and Hong Zheng and Xin Yan and Yunong Gao}, title = {Chemotherapy as Adjuvant Treatment for Early Stage Endometrial Cancer With High Intermediate Risk Factors}, volume = {28}, number = {7}, pages = {1285--1289}, year = {2018}, doi = {10.1097/IGC.0000000000001295}, publisher = {BMJ Specialist Journals}, abstract = {Objective The aim of this study was to explore the role of chemotherapy as adjuvant treatment for early-stage endometrial cancer (EC) with high-intermediate-risk (HIR) factors.Methods A prospective study of patients with early-stage EC with HIR factors for recurrence was performed between 2006 and 2014. A total of 96 patients were enrolled, and 50 patients received 3 cycles of platinum-based chemotherapy after surgery. Five-year disease-free survival and overall survival were evaluated.Results A total of 11 (11.5\%) of the 96 patients had recurrence, with a median recurrent time of 15.4 months. Of these 11 patients with recurrence, 2 received adjuvant chemotherapy after surgery, whereas 9 did not receive any treatment. Patients without adjuvant chemotherapy exhibited a significantly higher recurrence rate than those with adjuvant chemotherapy (19.6\% vs 4\%; P = 0.024). Meanwhile, patients with adjuvant chemotherapy had significantly higher 5-year disease-free survival compared with the control group (92.1\% vs 70.0\%, P = 0.024).Conclusions Chemotherapy is feasible and safe as adjuvant treatment for early-stage EC with HIR factors. Three cycles of platinum-based chemotherapy are sufficient for reducing the risk of recurrence. Further, large sample randomized studies are needed to confirm these results.}, issn = {1048-891X}, URL = {https://ijgc.bmj.com/content/28/7/1285}, eprint = {https://ijgc.bmj.com/content/28/7/1285.full.pdf}, journal = {International Journal of Gynecologic Cancer} }